The efficacy of the RET inhibitor Vandetanib was assessed in an SCLC phase II clinical trial carried out by the National Cancer Institute (NCI) of Canada Clinical Trials Group Study BR.20 [105]. Here, RET is linked to small cell lung carcinoma.